Marksans Pharma Limited (MARKSANS) Price & Analysis

Compare

3 Followers

MARKSANS Stock Chart & Stats

Day’s Range― - ―

52-Week Range₹168.05 - ₹358.50

Previous CloseN/A

Volume681.00K

Average Volume (3M)568.93K

Market Cap

₹78.49B

Enterprise Value₹97.16B

Total Cash (Recent Filing)₹7.05B

Total Debt (Recent Filing)₹3.22B

Price to Earnings (P/E)22.4

Beta1.54

Next Earnings

Nov 06, 2025

EPS EstimateN/A

Last Dividend Ex-Date

Aug 01, 2025

Dividend Yield0.47%

Share Statistics

EPS (TTM)1.30

Shares Outstanding453,163,760

10 Day Avg. Volume93,934

30 Day Avg. Volume568,930

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹271.00

Price Target Upside60.12% Upside

Rating ConsensusHold

Number of Analyst Covering1

Marksans Pharma Limited News

Marksans Pharma Announces AGM Notice Addendum

Marksans Pharma Limited ( ($IN:MARKSANS) ) has issued an announcement. Marksans Pharma Limited has announced an addendum to...

1M ago

Marksans Pharma Appoints New Secretarial Auditor for Five-Year Term

Marksans Pharma Limited ( ($IN:MARKSANS) ) just unveiled an announcement. Marksans Pharma Limited has announced the appointment of...

2M ago

Marksans Pharma to Engage Stakeholders at Upcoming Conference

An announcement from Marksans Pharma Limited ( ($IN:MARKSANS) ) is now available. Marksans Pharma Limited has announced its...

5M ago

Marksans Pharma’s Credit Rating Upgraded by India Ratings

Marksans Pharma Limited ( ($IN:MARKSANS) ) has provided an announcement. Marksans Pharma Limited has announced an upgrade in...

6M ago

MARKSANS FAQ

What was Marksans Pharma Limited’s price range in the past 12 months?

Marksans Pharma Limited lowest stock price was ₹168.05 and its highest was ₹358.50 in the past 12 months.

What is Marksans Pharma Limited’s market cap?

Marksans Pharma Limited’s market cap is ₹78.49B.

When is Marksans Pharma Limited’s upcoming earnings report date?

Marksans Pharma Limited’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.

How were Marksans Pharma Limited’s earnings last quarter?

Marksans Pharma Limited released its earnings results on Aug 12, 2025. The company reported ₹1.3 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.3.

Is Marksans Pharma Limited overvalued?

According to Wall Street analysts Marksans Pharma Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Marksans Pharma Limited pay dividends?

Marksans Pharma Limited pays a Annually dividend of ₹0.8 which represents an annual dividend yield of 0.47%. See more information on Marksans Pharma Limited dividends here

What is Marksans Pharma Limited’s EPS estimate?

Marksans Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Marksans Pharma Limited have?

Marksans Pharma Limited has 453,163,760 shares outstanding.

What happened to Marksans Pharma Limited’s price movement after its last earnings report?

Marksans Pharma Limited reported an EPS of ₹1.3 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -10.942%.

Which hedge fund is a major shareholder of Marksans Pharma Limited?

Currently, no hedge funds are holding shares in IN:MARKSANS

Company Description

Marksans Pharma Limited

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Marksans Pharma Limited (MARKSANS) Earnings & Revenues

Historic Earnings Reports

MARKSANS Stock 12 Month Forecast

Average Price Target

₹271.00

▲(60.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"202":"₹202","353":"₹353","239.75":"₹239.8","277.5":"₹277.5","315.25":"₹315.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":271,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹271.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":271,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹271.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":271,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹271.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[202,239.75,277.5,315.25,353],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,257.59,258.6215384615384,259.6530769230769,260.68461538461537,261.7161538461538,262.7476923076923,263.77923076923076,264.8107692307692,265.84230769230766,266.87384615384616,267.9053846153846,268.93692307692305,269.96846153846155,{"y":271,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,257.59,258.6215384615384,259.6530769230769,260.68461538461537,261.7161538461538,262.7476923076923,263.77923076923076,264.8107692307692,265.84230769230766,266.87384615384616,267.9053846153846,268.93692307692305,269.96846153846155,{"y":271,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,257.59,258.6215384615384,259.6530769230769,260.68461538461537,261.7161538461538,262.7476923076923,263.77923076923076,264.8107692307692,265.84230769230766,266.87384615384616,267.9053846153846,268.93692307692305,269.96846153846155,{"y":271,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":204.31,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":238.67,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":299.14,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":288.48,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":352.01,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":303.63,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":240.75,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":203.98,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":220.92,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":218.23,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":254.25,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":257.59,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":257.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >